Biotech | May 09, 2022
Roche Diabetes Care launches ACCU-FINE pen needles for virtually painless insulin delivery
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Go-ahead for pivotal clinical trial which is expected to commence by March
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Biocon Biologics and Viatris co-developed the products
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The centralized marketing authorization granted by the EC is valid in all EU Member
Subscribe To Our Newsletter & Stay Updated
